Receipt date: 02/20/2009

PTO/SB/08A (10-01)
Approved for use through 10/31/2002 OMR 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 1449A/PTO			Complete if Known		
				Application Number	10/522,074	
	INFORMATION D	DISCLOSURE		Filing Date	July 8, 2005	
	STATEMENT BY	APPLICANT		First Named Inventor	Darrell Sleep	
	(use as many sheet	s as necessary)			·	
	,			Art Unit	1654	
				Examiner Name	Gudibande	
Sheet	1	of	2	Attorney Docket Number	11055,204-US	

		U.	S PATENT DOCU	MENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 6,214,547	04-10-2001	Kjeldsen	
		US 5,795,746	08-18-1998	Kjeldsen	
		US 5,639,642	06-17-1997	Kjeldsen	
The same of the sa				,	
2000	-				
	-				
	_				
		-			
	_		-		
			The same of the sa		
			The state of the s		
				-	
		1			
		1			-
					1
	_	 			-
					0.00

		FOREIGN F	PATENT DOCU	MENTS		
Examiner Initials	Cite,	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т'
		EP 411893	02-06-1991	Eli Lilly and Company		$\overline{}$
		WO 93/18181	09-16-1993	Cornell Research		
		WO 96/29415	09-26-1996	Danisco		
-	-					
						\vdash
						\equiv
						Ξ
						_
Examine Signatur				Date Considered		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

*Applicant's unique oftation designation number (options), **See Kinds Codes of USPTO Patent Documents at www.uspla.org/cn/MPC Sended \$13.73. *For Japanese patent documents, the indication of the year of the religion of the Empirer must preced the sential occurrence, the process of the religion of the design of the design of the Empirer must preced the sential received by the religion of the design of the religion of

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner of Patents, Washington, DC 30231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/522,074	
INFORMATION DISCLOSURE				Filing Date	July 8, 2005	
	STATEMENT BY			First Named Inventor	Darrell Sleep	
	(use as many sheet	s as necessary)				
				Art Unit	1654	
				Examiner Name	Gudibande	
Sheet	2	of	2	Attorney Docket Number	11055 204-US	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T 2
		Elliot et al, "Secretion Of Glycosylated Human Erythropoletin*, Gene, vol. 79, pgs. 167-180 (1989)	
		Nottwehr S.F. et al., "Targeting Of Proteins Into The Eukaryotic Secretory Pathway; Signal Peptide Structure/Function Relationships", Bioessays, vol. 12, no. 10, pgs 478-484 (1990)	
/S.G./		Guo Meijing, Research Progresses In The Expression Of Recombinant Human Serum Albumin*, Advance in Biological Engineering, vol. 20, no. 5, ps. 39-42 (2000) Only Abstract was considered.	
		Gierasch L. M, "Signal Sequences" Biochemistry, vol. 28, no. 3, pgs. 923-930 (1989)	
			\
Examiner Signature	/Satv	anarayan Gudibande/ Date Considered 08/12/2009	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office. U.S. Patent and Trademark. Office, Washington, DC 20231. Do NOT SEND FES OR COMPLETE Patents, Washington, DC 20231.